Xiaoyan Bai, MD, PhD

Associate Professor
National Clinical Research Center for Kidney Disease
State Key Laboratory of Organ Failure Research
Division of Nephrology, Nanfang Hospital,Southern Medical University

Bai's research interests include podocyte injury and renal fibrosis research in diabetic nephropathy.  She is currently studying the mechanisms of lncRNAs, oxidative stress and lipid metabolism in the pathogenesis of diabetic nephropathy. Dr. Xiaoyan Bai is responsible for the Nanfang-Harvard Remote Discussion on Clinical Renal Pathology Conference and her team has established a novel mouse model of diabetic nephropathy in the resistant C57BL/6 mice, which makes it possible to interrogate the role of specific genetic modifications and to evaluate novel therapeutics for the treatment of DN in preclinical setting.

Dr. Bai earned her medical degree from Southern Medical University, Guangzhou, China. She then completed the postdoctoral training at UT Southwestern Medical Center.  She was awarded as the Distinguished Young Scholar at Nanfang Hospital.  She has received several grants and published over 30 papers in peer-reviewed journals.

As an associate professor at Nanfang Hospital, Southern Medical University, she is currently the Vice-President of the Youth Committee of Guangdong Society of Nephrology of Guangdong Provincial Medical Association and Committee member of the Youth Committee of CSN and member of the ISN, ASN and ISS.

Academic Title
Associate Professor

Education
Southern Medical University 2003

Selected Research and Publications

1.Li X , Xu L, Hou X, Geng J, Tian J, Liu X, Bai XY*. Advanced oxidation protein products aggravate tubulointerstitial fibrosis through PKC-dependent mitochondrial injury in early diabetic nephropathy. Antioxid Redox Signal. 2018 Feb 26. 

2.Bai XY, Geng J, Li X, Wan J, Liu J, Zhou ZM, Liu X. Long non-coding RNA LINC01619 regulates miR-27a/FOXO1 and endoplasmic reticulum stress-mediated podocyte injury in diabetic nephropathy. Antioxid Redox Signal. 2018 Feb 17; 118:71-84. 

3.Bai XY, Li X, Tian J, Xu L, Wan J, Liu Y. A new model of diabetic nephropathy in C57BL/6 mice challenged with advanced oxidation protein products. Free Radic Biol Med. 2018 Feb 17. pii: S0891-5849(18)30075-3. 

4.Wan J, Hou X, Zhou Z, Geng J, Tian J, Bai X*, Nie J. WT1 ameliorates podocyte injury via repression of EZH2/β-catenin pathway in diabetic nephropathy. Free Radic Biol Med. 2017 Jul;108:280-299. 

5.Zhou Z, Wan J, Hou X, Geng J, Li X, Bai X*. MicroRNA-27a promotes podocyte injury via PPARγ-mediated β-catenin activation in diabetic nephropathy. Cell Death Dis. 2017 Mar 9;8(3):e2658. 

6.Bai XY, Geng J, Zhou ZM, Tian JW, Li X. MicroRNA-130b/PPARγ signaling promotes renal tubulointerstitial fibrosis via activating VEGF-A/TGF-β/SNAIL pathway in diabetic nephropathy. Sci Rep. 2016 Feb 3;6:20475. 

7.Bai X, Geng J, Li X, Yang F, Tian J. VEGF-A Inhibition Ameliorates Podocyte Apoptosis via Repression of Activating Protein 1 in Diabetes. Am J Nephrol. 2014; 40:523-534.

8.Bai XY, Wu CL. Renal Cell Cancer and Mimics: Pathologic Primer for Radiologists. AJR Am J Roentgenol. 2012 Jun; 198(6):1289-93. 

9.Bai XY, Li X, Wan L, Wang G, Jia N, Geng J. Intravascular large B-cell lymphoma of the kidney: a case report. Diagnostic Pathology. 2011 Sep 23; 6: 86. 

10.Bai XY, Basgen JM. Podocyte number in the maturing rat kidney. Am J Nephrol. 2011; 33(1): 91-6.